Clinical trials: in Bulgaria
Systemic Lupus Erythematosus
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
This study aims to examine the efficacy and safety of obexelimab in participants with systemic lupus erythematosus (SLE).
- Trial name
- SunStone (NCT06559163)
- Testing
- Obexelimab
- Where
- 110 sites in United States, Belgium and 16 more
- Volunteers
- 190 people
- Sponsor
- Zenas BioPharma (USA), LLC
Relapsing Multiple Sclerosis
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
- Trial name
- NCT05147220
- Testing
- Remibrutinib, Teriflunomide
- Where
- 200 sites in United States, Argentina and 32 more
- Volunteers
- 1,000 people
- Sponsor
- Novartis Pharmaceuticals
Obesity, Heart Failure
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body…
- Trial name
- HF-POLARIS (NCT07567001)
- Testing
- NNC0487-0111
- Where
- 838 sites in United States, Argentina and 25 more
- Volunteers
- 5,610 people
- Sponsor
- Novo Nordisk A/S
Relapsing Multiple Sclerosis
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
- Trial name
- NCT05156281
- Testing
- Remibrutinib, Teriflunomide
- Where
- 223 sites in United States, Argentina and 25 more
- Volunteers
- 1,007 people
- Sponsor
- Novartis Pharmaceuticals
Ulcerative Colitis
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
The main aim of this study is to learn if TAK-279 reduces bowel inflammation and symptoms compared to placebo. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well…
- Trial name
- NCT06254950
- Testing
- TAK-279
- Where
- 141 sites in United States, Australia and 20 more
- Volunteers
- 213 people
- Sponsor
- Takeda
Obesity, Overweight
AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
This study is being done to look at the safety and effect of NNC0487-0111 in people with excess body weight and knee osteoarthritis when compared to placebo.
- Conditions
- Obesity, Overweight, Osteoarthritis, Knee
- Trial name
- AMAZE 6 (NCT07509307)
- Testing
- NNC0487-0111
- Where
- 81 sites in United States, Australia and 9 more
- Volunteers
- 400 people
- Sponsor
- Novo Nordisk A/S
Hereditary Angioedema, Hereditary Angioedema Type I
Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II
This study evaluates the safety and efficacy of PHA-022121 administered orally for prophylaxis against angioedema attacks in patients with hereditary angioedema (HAE).
- Conditions
- Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II
- Trial name
- HAE CHAPTER-1 (NCT05047185)
- Testing
- Deucrictibant low dose, Deucrictibant high dose
- Where
- 19 sites in United States, Austria and 7 more
- Volunteers
- 34 people
- Sponsor
- Pharvaris Netherlands B.V.
Cataract Senile
Extended Depth of Focus (EDF) Intraocular Lens (IOL) Versus Monofocal Intracoular Lens (IOL)
Extended depth of focus (EDF) intraocular lens (IOL) versus Monofocal intraocular lens (IOL)
- Trial name
- NCT07092020
- Testing
- EDF, Monofocal IOL
- Where
- 14 sites in Bulgaria, Czechia and 2 more
- Volunteers
- 220 people
- Sponsor
- Carl Zeiss Meditec AG
Psychosis Associated With Alzheimer's Disease
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
This is a Phase 3, 38-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with psychosis associated with Alzheimer's Disease.
- Trial name
- NCT05511363
- Testing
- KarXT
- Where
- 129 sites in United States, Bulgaria and 11 more
- Volunteers
- 410 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Dry Eye Disease (DED)
New Preservative-free Combination of Trehalose, Sodium Hyaluronate and N-acetyl-aspartyl-glutamate (NAAGA) in Dry Eye
The goal of this prospective, non-randomized, non-comparative, monocentric PMCF study is to assess the performance of a new preservative-free combination of trehalose, sodium hyaluronate and NAAGA on DED at 6 months in 30…
- Trial name
- NCT06903741
- Testing
- T2769
- Where
- Bulgaria
- Volunteers
- 30 people
- Sponsor
- Laboratoires Thea
Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
This is a Phase 3 extension, global, multicenter study to assess the long-term safety and tolerability of tolebrutinib in adult participants (aged ≥18 years) with RMS, PPMS, or NRSPMS who were previously enrolled in the Phase 2b…
- Conditions
- Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
- Trial name
- NCT06372145
- Testing
- Tolebrutinib, Teriflunomide
- Where
- 352 sites in United States, Argentina and 45 more
- Volunteers
- 2,500 people
- Sponsor
- Sanofi
Rheumatoid Arthritis
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how safe and effective upadacitinib is in treating RA when compared to adalimumab in…
- Trial name
- SELECT- SWITCH (NCT05814627)
- Testing
- Upadacitinib, Adalimumab
- Where
- 218 sites in United States, Argentina and 23 more
- Volunteers
- 487 people
- Sponsor
- AbbVie
Heart Failure
Alleviant ALLAY-HF Study
Prospective, multicenter, randomized, sham-controlled, double blinded, adaptive study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with…
- Trial name
- NCT05685303
- Testing
- Alleviant ALV1 System
- Where
- 93 sites in United States, Australia and 12 more
- Volunteers
- 700 people
- Sponsor
- Alleviant Medical, Inc.
Crohn's Disease
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
The study consists of 4 sub-studies, as follows: Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safety of risankizumab versus placebo as maintenance therapy in participants with…
- Trial name
- FORTIFY (NCT03105102)
- Testing
- Risankizumab IV, Risankizumab SC, Risankizumab On-Body Injector (OBI)
- Where
- 496 sites in United States, Argentina and 45 more
- Volunteers
- 1,336 people
- Sponsor
- AbbVie
Hemophilia A, Hemophilia B
Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B
Treatment with PF-06741086 is anticipated to demonstrate a clinically relevant advantage and/or a major contribution to patient care in comparison to current methods of treatment for hemophilia A or B because it works differently…
- Trial name
- NCT03938792
- Testing
- PF-06741086
- Where
- 62 sites in United States, Bulgaria and 18 more
- Volunteers
- 188 people
- Sponsor
- Pfizer
Chronic Obstructive Pulmonary Disease
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment…
- Trial name
- NCT05878769
- Testing
- Astegolimab
- Where
- 481 sites in United States, Argentina and 38 more
- Volunteers
- 2,000 people
- Sponsor
- Hoffmann-La Roche
Dermatitis Atopic
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm monotherapy study for treatment of participants diagnosed with moderate to severe atopic dermatitis (AD), whose…
- Trial name
- NCT06181435
- Testing
- Amlitelimab
- Where
- 142 sites in United States, Argentina and 14 more
- Volunteers
- 589 people
- Sponsor
- Sanofi
Urothelial Carcinoma, Non-Small Cell Lung Cancer
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
This is a non-interventional, multi-country, multi-centre, multiple cohort prospective study, with retrospective collection of prior medical/treatment history data from medical records, designed to assess the real-world outcomes…
- Conditions
- Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Hepatocellular Carcinoma
- Trial name
- IMreal (NCT03782207)
- Testing
- Atezolizumab
- Where
- 257 sites in Argentina, Austria and 28 more
- Volunteers
- 2,756 people
- Sponsor
- Hoffmann-La Roche
Chronic Myelogenous Leukemia
Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients
The main purpose of the study was to investigate whether nilotinib treatment can be safely suspended with no recurrence of CML in selected patients who responded optimally on this treatment
- Trial name
- ENESTfreedom (NCT01784068)
- Testing
- Nilotinib followed by treatment-free
- Where
- 113 sites in United States, Argentina and 17 more
- Volunteers
- 215 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Advanced Breast Cancer
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one…
- Conditions
- Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
- Trial name
- OPERA-01 (NCT06016738)
- Testing
- Palazestrant, Fulvestrant, Anastrozole
- Where
- 233 sites in United States, Argentina and 24 more
- Volunteers
- 510 people
- Sponsor
- Olema Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.